Marktanalyse - Post-Operative Pain - Pipeline Review, H1 2017

Global Markets Direct
02.2017
187 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Post-Operative Pain - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain — Pipeline Review, H1 2017, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 9, 16, 10, 13, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Post-Operative Pain - Overview 8

Post-Operative Pain - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 19

Post-Operative Pain - Therapeutics Assessment 20

Assessment by Target 20

Assessment by Mechanism of Action 23

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Post-Operative Pain - Companies Involved in Therapeutics Development 30

AcelRx Pharmaceuticals Inc 30

Adynxx Inc 30

AngioChem Inc 31

Aoxing Pharmaceutical Company Inc 31

AskAt Inc 31

Boehringer Ingelheim GmbH 32

Camurus AB 33

Cara Therapeutics Inc 33

Colby Pharmaceutical Company 34

Cytogel Pharma LLC 34

Dompe Farmaceutici SpA 35

DURECT Corp 35

Eupraxia Pharmaceuticals Inc 36

EyeGate Pharmaceuticals Inc 36

Fujimoto Pharmaceutical Corp 37

Grunenthal GmbH 37

GW Pharmaceuticals Plc 38

Heron Therapeutics Inc 38

Immupharma Plc 39

Innocoll AG 39

INSYS Therapeutics Inc 40

iX Biopharma Ltd 40

Laboratorios Del Dr Esteve SA 41

Lipocure Ltd 41

Liquidia Technologies Inc 42

Medtronic Plc 42

Novartis AG 43

Orbis Biosciences Inc 43

Orion Oyj 44

Pacira Pharmaceuticals Inc 44

PainReform Ltd 45

Pharmazz Inc 45

PhytoHealth Corp 46

PixarBio Corp 46

Proteus SA 47

Recro Pharma Inc 47

Relmada Therapeutics Inc 48

Serina Therapeutics Inc 48

SteadyMed Therapeutics Inc 49

Teikoku Pharma USA Inc 49

The Medicines Company 50

Trevena Inc 50

Post-Operative Pain - Drug Profiles 51

(bupivacaine hydrochloride + meloxicam) ER - Drug Profile 51

(buprenorphine hydrochloride + granisetron hydrochloride) ER - Drug Profile 54

A-100 - Drug Profile 55

ANG-2002 - Drug Profile 56

ARX-04 - Drug Profile 57

AYX-1 - Drug Profile 64

BI-1026706 - Drug Profile 67

bupivacaine hydrochloride - Drug Profile 69

bupivacaine hydrochloride - Drug Profile 70

bupivacaine hydrochloride - Drug Profile 71

bupivacaine hydrochloride - Drug Profile 72

bupivacaine hydrochloride SR - Drug Profile 74

bupivacaine hydrochloride SR - Drug Profile 79

buprenorphine hydrochloride - Drug Profile 80

CAM-2048 - Drug Profile 81

carbamazepine - Drug Profile 82

CPC-111 - Drug Profile 83

CPC-123 - Drug Profile 84

Cyt-1010 - Drug Profile 85

dexamethasone acetate - Drug Profile 87

dexmedetomidine hydrochloride - Drug Profile 92

DF-2755A - Drug Profile 93

difelikefalin - Drug Profile 94

ECP-1014 - Drug Profile 103

fadolmidine hydrochloride - Drug Profile 104

fentanyl - Drug Profile 105

gonyautoxin - Drug Profile 106

grapiprant - Drug Profile 107

HTX-009 - Drug Profile 109

HYLP-002 - Drug Profile 110

IPP-102199 - Drug Profile 111

ketamine hydrochloride - Drug Profile 112

ketorolac tromethamine - Drug Profile 114

lacosamide - Drug Profile 115

levorphanol tartrate ER - Drug Profile 116

MDT-10013 - Drug Profile 118

meloxicam - Drug Profile 119

meloxicam ER - Drug Profile 123

MR-309 - Drug Profile 124

nabiximols - Drug Profile 126

nalbuphine hydrochloride - Drug Profile 133

neosaxitoxin - Drug Profile 134

oliceridine - Drug Profile 136

oxethazaine - Drug Profile 141

PMZ-2010 - Drug Profile 142

RBM-004 - Drug Profile 144

ropivacaine - Drug Profile 145

ropivacaine ER - Drug Profile 146

SAF-312 - Drug Profile 147

SER-226 - Drug Profile 148

Small Molecule for Post-Operative Pain - Drug Profile 149

sufentanil citrate - Drug Profile 150

tapentadol hydrochloride - Drug Profile 158

tilidine hydrochloride - Drug Profile 160

tramadol hydrochloride - Drug Profile 161

tramadol hydrochloride ER - Drug Profile 162

URB-937 - Drug Profile 163

VVZ-149 - Drug Profile 164

Post-Operative Pain - Dormant Projects 165

Post-Operative Pain - Discontinued Products 168

Post-Operative Pain - Product Development Milestones 169

Featured News & Press Releases 169

Appendix 182

Methodology 182

Coverage 182

Secondary Research 182

Primary Research 182

Expert Panel Validation 182

Contact Us 182

Disclaimer 183





List of Tables

Number of Products under Development for Post-Operative Pain, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H1 2017

Post-Operative Pain - Pipeline by Adynxx Inc, H1 2017

Post-Operative Pain - Pipeline by AngioChem Inc, H1 2017

Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017

Post-Operative Pain - Pipeline by AskAt Inc, H1 2017

Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017

Post-Operative Pain - Pipeline by Camurus AB, H1 2017

Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H1 2017

Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H1 2017

Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H1 2017

Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H1 2017

Post-Operative Pain - Pipeline by DURECT Corp, H1 2017

Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2017

Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017

Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2017

Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2017

Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H1 2017

Post-Operative Pain - Pipeline by Heron Therapeutics Inc, H1 2017

Post-Operative Pain - Pipeline by Immupharma Plc, H1 2017

Post-Operative Pain - Pipeline by Innocoll AG, H1 2017

Post-Operative Pain - Pipeline by INSYS Therapeutics Inc, H1 2017

Post-Operative Pain - Pipeline by iX Biopharma Ltd, H1 2017

Post-Operative Pain - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017

Post-Operative Pain - Pipeline by Lipocure Ltd, H1 2017

Post-Operative Pain - Pipeline by Liquidia Technologies Inc, H1 2017

Post-Operative Pain - Pipeline by Medtronic Plc, H1 2017

Post-Operative Pain - Pipeline by Novartis AG, H1 2017

Post-Operative Pain - Pipeline by Orbis Biosciences Inc, H1 2017

Post-Operative Pain - Pipeline by Orion Oyj, H1 2017

Post-Operative Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2017

Post-Operative Pain - Pipeline by PainReform Ltd, H1 2017

Post-Operative Pain - Pipeline by Pharmazz Inc, H1 2017

Post-Operative Pain - Pipeline by PhytoHealth Corp, H1 2017

Post-Operative Pain - Pipeline by PixarBio Corp, H1 2017

Post-Operative Pain - Pipeline by Proteus SA, H1 2017

Post-Operative Pain - Pipeline by Recro Pharma Inc, H1 2017

Post-Operative Pain - Pipeline by Relmada Therapeutics Inc, H1 2017

Post-Operative Pain - Pipeline by Serina Therapeutics Inc, H1 2017

Post-Operative Pain - Pipeline by SteadyMed Therapeutics Inc, H1 2017

Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, H1 2017

Post-Operative Pain - Pipeline by The Medicines Company, H1 2017

Post-Operative Pain - Pipeline by Trevena Inc, H1 2017

Post-Operative Pain - Dormant Projects, H1 2017

Post-Operative Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017

Post-Operative Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017

Post-Operative Pain - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Post-Operative Pain, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus